Roche, Pfizer win FDA nods for targeted cancer drugs

Roche ($RHHBY) and Genentech won a landmark approval for the cancer drug vismodegib today. After gaining significant efficacy data from a Phase II study on basal cell carcinoma, the drug giant not only went straight to the regulators for a decision, but also won the approval well ahead of the agency's deadline. And top regulators signaled that they would look kindly on other developers who take the same approach to targeted therapeutics. The FDA nod comes on top of another targeted-drug approval Friday, for Pfizer's ($PFE) advanced kidney cancer drug axitinib, which will be marketed as Inlyta. Article | Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.